Modality
mAb
MOA
VEGFi
Target
FLT3
Pathway
Amyloid
NBGastric Ca
Development Pipeline
Preclinical
~Sep 2012
→ ~Dec 2013
Phase 1
~Mar 2014
→ ~Jun 2015
Phase 2
~Sep 2015
→ ~Dec 2016
Phase 3
Mar 2017
→ Feb 2031
Phase 3Current
NCT05589801
2,941 pts·NB
2017-03→2030-07·Recruiting
NCT08231177
957 pts·NB
2023-08→TBD·Completed
NCT06456444
2,401 pts·NB
2018-04→2031-02·Recruiting
6,299 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-07-184.3y awayPh3 Readout· NB
2031-02-114.9y awayPh3 Readout· NB
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P3
Recruit…
P3
Recruit…
P3
Complet…
Catalysts
Ph3 Readout
2030-07-18 · 4.3y away
NB
Ph3 Readout
2031-02-11 · 4.9y away
NB
RecruitingCompleted|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05589801 | Phase 3 | NB | Recruiting | 2941 | LiverFat |
| NCT08231177 | Phase 3 | NB | Completed | 957 | Biomarker |
| NCT06456444 | Phase 3 | NB | Recruiting | 2401 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Gozeosocimab | Illumina | Phase 2 | BCMA |